• Publications
  • Influence
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
F. A. Peccatori1, H. A. Azim Jr2, R. Orecchia3, H. J. Hoekstra4, N. Pavlidis5, V. Kesic6 & G. Pentheroudakis5, on behalf of the ESMO Guidelines Working Group* Fertility and Procreation Unit, DivisionExpand
  • 416
  • 26
Dissecting the heterogeneity of triple-negative breast cancer.
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. TNBC isExpand
  • 325
  • 13
  • PDF
Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.
PURPOSE We questioned the impact of pregnancy on disease-free survival (DFS) in women with history of breast cancer (BC) according to estrogen receptor (ER) status. PATIENTS AND METHODS AExpand
  • 187
  • 11
  • PDF
An update on PARP inhibitors—moving to the adjuvant setting
Inhibition of poly(ADP-ribose) polymerase (PARP) enzymes is a potential synthetic lethal therapeutic strategy in cancers harbouring specific DNA-repair defects, including those arising in carriers ofExpand
  • 246
  • 9
Cancer and fertility preservation: international recommendations from an expert meeting
In the last years, thanks to the improvement in the prognosis of cancer patients, a growing attention has been given to the fertility issues. International guidelines on fertility preservation inExpand
  • 313
  • 7
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete
BACKGROUND Findings from the randomised phase 3 NeoALTTO trial in women with HER2-positive early breast cancer showed that the combination of lapatinib and trastuzumab significantly improved rates ofExpand
  • 267
  • 6
Understanding the biology of triple-negative breast cancer.
Greater understanding of the biology of triple-negative breast cancer (TNBC) is needed to discern the roughly 60% of node-negative patients who are already cured with locoregional therapy from theExpand
  • 120
  • 6
Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies.
BACKGROUND Pregnancy-associated breast cancer (PABC) is relatively rare with considerable controversy regarding its prognosis. PATIENTS & METHODS Two of the authors independently performed aExpand
  • 142
  • 5
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast
The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor (HR) positive metastatic breast cancer (MBC).Expand
  • 157
  • 5
Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling
Purpose: Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures in predicting prognosis in young women and to understand biologicalExpand
  • 222
  • 5
  • PDF